A novel sensitive immunoassay targeting the MTX-Lipoarabinomannan epitope meets the WHO's performance target for Tuberculosis diagnosis SUPPLEMENTARY MATERIALS
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Supplementary Fig. S1 . Oligosaccharide structures used for antibody epitope mapping. A total of 61 structures were used in testing. Selected oligosaccharides (Gly 16, Gly 22, and Gly 44) were further used for the development of rabbit monoclonal antibodies Supplementary Fig. S2 . Results of epitope mapping using glycan arrays. Reactivity of monoclonal antibodies at a concentration of 0.039 µg/mL to selected oligosaccharide structures. Dark green areas represent strong binding, white areas no-or low blinding. The figure includes all glycans to which reactivity over background was shown for at least one antibody. Refer to Supplementary Figure S1 for the names used in column one. performance of six different anti-LAM capture antibodies combined with the A194-01 detection antibody. The results were determined from eight point calibration curves as described in Figure 2 . The first two data columns show average signal and CV for the blank sample (n = 14). The third shows the average CV for calibration standards providing signals above our detection threshold of 1.375-fold above the blank signal (based on four replicates per LAM concentration). The final column shows the estimates for limit of detection (LOD) based on the LAM concentration expected to give a signal equal to the detection threshold as calculated by back-fitting to the best 4-PL fit to the calibration curve. Supplementary Table S2 . Effect of urine matrix on LAM assay quantitation. Matrix effects were assessed by carrying out spike recovery and dilution linearity experiments for each of the 6 capture antibodies when paired with the A194-01 detection antibody. Spike recovery is the measured LAM value for bacterial LAM spiked into a urine sample, relative to the theoretical expected value. Each entry is the average recovery for three concentrations (300, 3,000 and 30,000 pg/mL) of LAM spiked into a sample. The recovery on dilution is the measured LAM value for a diluted LAM-positive urine sample relative to the expected value based on the measured urinary LAM in the undiluted sample (as quantitated using the FIND 28 capture, the LAM levels in the undiluted samples ranged from roughly 1,000 to roughly 200,000 pg/mL). Each value is the average recovery for four dilutions ranging from 1:2 to 1:16. The 
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